Sign In
Buy LLY
$1,192.80
+22.94 (+1.96%)
At Close: Aug 06, 2026
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
12:59pm, Tuesday, 25'th Mar 2025
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the health care system is improving.
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
11:25am, Tuesday, 25'th Mar 2025
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment
Eli Lilly Shares Rise Over 2% After Key Signal
05:13pm, Monday, 24'th Mar 2025
LLY CLIMBS OVER 17 POINTS AT ITS HIGH
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
01:29pm, Monday, 24'th Mar 2025
Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year. The trial results are among the pharmaceutical
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
09:45am, Monday, 24'th Mar 2025
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
Is Ozempic maker Novo Nordisk losing to Eli Lilly in the obesity wars?
09:31am, Monday, 24'th Mar 2025
Eli Lilly and Co (NYSE:LLY) is tightening its grip on the obesity drug market, with its injectable treatment Zepbound gaining momentum over Novo Nordisk's Wegovy, according to Berenberg. The investmen
Sesame, America's Low-Cost Leader in Healthcare, Streamlines Access for Eligible Patients to Lilly's Obesity Medicine Zepbound
08:31am, Monday, 24'th Mar 2025
New integration means streamlined ordering and paying experiences for patients, with the same direct shipping and the best self-pay price on single-dose Zepbound vials New integration means streamline
Market Sell-Off: Can Buying These 3 "Safe" Stocks Today Set You Up for Life?
08:00am, Monday, 24'th Mar 2025
The U.S. equity market has had a solid run in the past two years, buoyed by a steadily improving macroeconomic environment and strong uptake of artificial intelligence technologies. The benchmark S&P
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly
04:43am, Sunday, 23'rd Mar 2025
It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and accor
Eli Lilly: Growth With Higher Margins
09:38am, Friday, 21'st Mar 2025
The Eli Lilly and Company investment thesis highlights a robust 2024 performance, driven by a strong pipeline and solid balance sheet, supporting a positive future outlook. The company's strong cash f
Lilly's weight-loss drug launch in India to energize rivals eyeing mega market
12:06pm, Thursday, 20'th Mar 2025
Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.
5 Reasons It's Not Too Late to Buy Eli Lilly Stock
05:25am, Thursday, 20'th Mar 2025
Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable healthcare company in the world, with a market cap of $730 billion.
Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval
02:54am, Thursday, 20'th Mar 2025
Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from country's drug regulator, it said on Thursday.
Eli Lilly: A Safe Harbor Amid Market Volatility
02:58pm, Monday, 17'th Mar 2025
My DCF analysis suggests that Eli Lilly's stock is 60% undervalued. Defensive healthcare stocks like Eli Lilly are favorable in the current uncertain macroenvironment, driven by tariff concerns and st
NVO vs. LLY: Which Stock Is the Better Value Option?
12:46pm, Monday, 17'th Mar 2025
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novo Nordisk (NVO) and Eli Lilly (LLY). But which of these two stocks is more attractive to valu
